Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 2, 1998, Pages 396-402

  Mortensen, Lene ^a   Charles, Peder ^a   Bekker, Pirow J ^b   Digennaro, Joseph ^b   Johnston Jr , C Conrad ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISEDRONIC ACID;

ADULT; ARTHRALGIA; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALKALINE PHOSPHATASE; AMINO ACIDS; BONE DENSITY; CALCIUM CHANNEL BLOCKERS; CREATININE; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; POSTMENOPAUSE; TIME FACTORS;

EID: 0031733092     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.2.396     Document Type: Article

References (15)

1. Lindsay R, Coutts JRT, Sweeney A, Hart DM. 1984 Endogenous estrogen and bone loss following oophorectomy. Calcif Tissue Res. 22:213-216.
2. Johnston CC, Hui SL, Witt RM, Appledorn R, Baker RS, Longcope C. 1985 Early menopausal changes in bone mass and sex steroids. Clin Endocrinol Metab. 61:905-911.
3. Albright F. 1947 The effect of hormones on esteogenesis in man. Recent Prog Horm Res. 1:293-353.
4. Davis ME, Lanzl LH, Cox AB. 1970 Detection, prevention and retardation of postmenopausal osteoporosis. Obstet Gynecol. 36:187-198.
5. Lindsay R, Aitken JM, Anderson JB, Hart DM, MacDonald EB, Clark AC. 1976 Long-term prevention of postmenopausal osteoporosis by estrogen. Lancet. i:1038-1041.
6. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. 1989 Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res. 15:389-396.
7. Roux C, Ravaud P, Cohen-Solal MC, et al. 1994 Biologic, histologic, and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone. 15:41-49.
8. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy G. 1993 Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab. 77:1067-1071.
9. Brown JP, Kylstra JW, Bekker PJ, et al. 1994 Risedronate in Paget's disease: preliminary results of a multicenter study. Semin Arthritis Rheum. 23:272.
10. Chines A, Bekker P, Clarke P, Hosking D. 1996 Reduction of bone pain and alkaline phosphatase in patients with severe Paget's disease of bone following treatment with risedronate. J Bone Miner Res. 11(suppl 1):S371. Abstract.
11. Lindsay R, Cosman F, Herrington BS, Himmelstein S. 1992 Bone mass and body composition in normal women. J Bone Miner Res. 7:55-63.
12. Lindsay R, Hart DM, Clark DM. 1984 The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 63:759-763.
13. Lindsay R, Hart DM, MacLean A, Clark AC, Kraszewski A, Garwood J. 1978 Bone response to termination of estrogen treatment. Lancet. i:1325-1327.
14. Christiansen C, Christiansen MS, Transbol I. 1981 Bone mass in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy Lancet. i:459-461.
15. Horsman A, Nordin BE, Crilly RG. 1979 Effect on bone of withdrawal of estrogen therapy. Lancet. ii:33.